Merck stock declined in 2024, but 2025 could see growth with Keytruda and potential FDA approval.

From Nasdaq: 2025-01-21 00:35:13

Merck stock (NYSE: MRK) declined by 10% in 2024, underperforming the S&P 500. Keytruda sales reached $28 billion, but Gardasil faced challenges in China. MRK stock closed at $99, with a volatile history. 2025 could see growth with Keytruda, but competition for diabetes drugs. Merck’s animal health business may benefit from increased pet ownership in the U.S.

2025 could bring positive developments for Merck, with Keytruda leading growth and potential FDA approval for clesrovimab. MRK stock, trading at 4x trailing revenues, has headwinds priced in. Peers’ performance metrics show Merck’s potential upside. Trefis’ High-Quality Portfolio has outperformed the S&P 500 since 2016. In January 2025, MRK had a 1% return, while the S&P 500 had a 24% return since the start of 2024. 1. The stock market hit record highs as the Dow Jones Industrial Average rose by 200 points, reaching a new all-time high of 30,000. This surge was driven by positive news on vaccine developments and hopes for a strong economic recovery in 2021.

2. In a groundbreaking study, researchers have found that a new drug has the potential to reduce the risk of heart attacks and strokes by 30%. The drug, known as Vascepa, could be a game-changer in preventing cardiovascular diseases and improving overall heart health.

3. The United Nations reported that global carbon emissions are set to decrease by 7% in 2020 due to the COVID-19 pandemic. This marks the largest annual drop in emissions since World War II. However, experts warn that this reduction is temporary and more action is needed to combat climate change.

4. Tesla CEO Elon Musk announced plans to build a new Gigafactory in Texas, which will produce the Cybertruck and Model Y vehicles. The factory is expected to create thousands of jobs and boost the local economy. This move reaffirms Tesla’s commitment to expanding its operations in the US.

5. President-elect Joe Biden unveiled his economic team, including Janet Yellen as Treasury Secretary and Neera Tanden as Director of the Office of Management and Budget. Yellen, a former Federal Reserve Chair, is expected to focus on rebuilding the economy and addressing income inequality in the wake of the pandemic.



Read more at Nasdaq: What’s New With Merck? | Nasdaq